Oral Orforglipron Maintains Modest Weight Loss After Stopping Injectables, Trial Finds

Daily oral orforglipron helped patients maintain most of the weight they had lost on injectable medications, according to a study published in Nature Medicine. 7 per cent of their weight reduction. 2 per cent.

Former semaglutide patients fared similarly. 6 per cent. The trial enrolled 376 participants across the United States who had previously undergone treatment with either tirzepatide or semaglutide for 72 weeks.

Participants were randomly assigned to receive either orforglipron or a placebo daily for twelve months. Orforglipron is manufactured by Eli Lilly and belongs to the GLP-1 agonist class of drugs, which reduce appetite, slow digestion and lower blood sugar levels. The US Food and Drug Administration approved orforglipron last month, though it remains unlicensed in Britain.

Individuals using weight loss injections typically regain weight after stopping treatment. The new findings suggest an oral option may interrupt that pattern for many patients. A separate research paper titled "A brain reward circuit inhibited by next-generation weight-loss drugs in mice" was published in Nature on the same day.

Dr Marie Spreckley, research programme manager at the University of Cambridge, said the study reflected real-world conditions. "One of the most valuable aspects of this study is that it reflects a highly realistic clinical scenario," she said. Dr Spreckley added that many people do not want to remain on injectable therapy indefinitely due to treatment burden, convenience, travel, storage requirements, cost or personal preference.

She noted that switching to an oral treatment while keeping much of the weight off could represent an important additional option within longer-term obesity care pathways. Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, pointed to the financial barriers of injectable medications.

He said they carry substantial costs which limits their long-term applicability both for private purchasers and the NHS.

Oral alternatives are considerably less expensive to produce even if they do not achieve quite the same results as injections, Dr Cork said. Dr Cork added that further investigation involving larger patient cohorts would be necessary. The trial results come as demand for weight-loss drugs continues to grow following the success of tirzepatide, sold as Mounjaro, and semaglutide, sold as Wegovy.